ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP33-20 Updates to Telemedicine/Telehealth and Telephone Call Reimbursement Policies
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 25, 2020
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 2091 - 2100 လၢ 4229 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP28-20 Updated Service Type Options for Surgery on Availity Portal
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 25, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP29-20 Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Peanut Allergy
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 25, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP30-20 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Oxbryta™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 25, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP31-20 Commercial Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Oxbryta™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 25, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2020 March Provider Press
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 24, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP8-20 Medical Drug Update for New to Market Golodirsen (Vyondys 53)
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 08, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP25-20 Pharmacy Benefit Exclusion for Injectafer®, Feraheme®, Venofer®, INFeD®, Ferrlecit®, and generic Ferrlecit®
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 11, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP26-20 CMS Decision Memo on Acupuncture for Chronic Low Back Pain
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 11, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP24-20 Pharmacy Benefit Update – Addition of Drugs to Existing Prior Authorization (PA) with Quantity Limit (QL) Programs
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 11, 2020